Biotech RadarJobs updated

COMPANY

ArriVent Biopharma

HQ: Newtown Square, PA source · arrivent.com ↗

Clinical Phase 3

Location: Newtown Square, PA · source · Oct 6, 2026

Profile checked Oct 10, 2026

Keywords: Metastatic Non-Small-Cell Lung Cancer Advanced Non-Small-Cell Lung Cancer EGFR Exon 20 Mutations Ovarian Cancer Endometrial Cancer Platinum-resistant Ovarian Cancer Metastatic Ovarian Cancer Metastatic Endometrial Cancer Non-Small-Cell Lung Cancer EGFR P-Loop and Alpha C-Helix Compressing EGFR PACC EGFR Uncommon Mutations Locally Advanced or Metastatic Solid Tumors Colorectal Cancer Gastric Cancer Pancreatic Cancer Non-Small Cell Lung Cancer HER2 Exon 20 Mutations Including G719X and S768I EGFR Uncommon Mutations ARR-002 MRG007

$75.0MRaised (2 yrs)5Trials (company is sponsor)

Timeline

  1. Trial start 1: Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. source ↗
  2. Trial start Phase 3: Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NS source ↗
  3. Trial start Phase 1: A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors source ↗
  4. Raise Follow-on offering: $75M (total, as published), announced Jul 1, 2025. Source: SEC filing. source ↗
  5. Trial start Phase 3: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) source ↗
  6. Trial start Phase 1: Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epiderm source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $75.0M. Last 2 years.

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT07755436Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.1RecruitingJul 23, 20262027-08 (estimated)
NCT07185997Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsPhase 3RecruitingDec 17, 20252029-02 (estimated)
NCT07066657A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsPhase 1RecruitingJul 25, 20252028-03 (estimated)
NCT05364073Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsPhase 1Active, not recruitingJun 30, 2022Jun 3, 2025 (actual)
NCT05607550Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Phase 3Active, not recruitingJun 1, 2023Aug 15, 2025 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback